Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SANTORO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.456
EU - Europa 1.698
AS - Asia 1.592
SA - Sud America 246
AF - Africa 44
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.410
SG - Singapore 685
RU - Federazione Russa 509
IT - Italia 435
CN - Cina 335
BR - Brasile 197
VN - Vietnam 144
DE - Germania 143
HK - Hong Kong 141
FI - Finlandia 140
PL - Polonia 102
GB - Regno Unito 70
FR - Francia 67
JP - Giappone 57
SE - Svezia 48
IN - India 45
BD - Bangladesh 41
NL - Olanda 35
IE - Irlanda 31
CA - Canada 23
RO - Romania 22
AR - Argentina 20
TR - Turchia 20
UA - Ucraina 19
PK - Pakistan 18
ES - Italia 17
KR - Corea 16
BE - Belgio 15
MX - Messico 15
IQ - Iraq 13
ZA - Sudafrica 12
AT - Austria 11
UZ - Uzbekistan 10
ID - Indonesia 9
IR - Iran 9
MA - Marocco 7
CH - Svizzera 6
CL - Cile 6
NP - Nepal 6
PY - Paraguay 6
EC - Ecuador 5
JO - Giordania 5
MY - Malesia 5
RS - Serbia 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
CO - Colombia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
ET - Etiopia 4
IL - Israele 4
KE - Kenya 4
OM - Oman 4
SA - Arabia Saudita 4
TN - Tunisia 4
AU - Australia 3
CR - Costa Rica 3
EG - Egitto 3
GR - Grecia 3
KG - Kirghizistan 3
PH - Filippine 3
DK - Danimarca 2
HR - Croazia 2
JM - Giamaica 2
KZ - Kazakistan 2
LT - Lituania 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LY - Libia 1
MG - Madagascar 1
ML - Mali 1
MM - Myanmar 1
PR - Porto Rico 1
QA - Qatar 1
SI - Slovenia 1
SR - Suriname 1
SV - El Salvador 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.042
Salva come PNG Salva come JPEG
Città #
Ashburn 491
Singapore 452
Fairfield 401
Chandler 272
Woodbridge 180
Wilmington 162
San Jose 157
Houston 148
Hong Kong 138
Cambridge 136
Seattle 135
Council Bluffs 110
Helsinki 99
Ann Arbor 89
Zgierz 84
Moscow 80
Beijing 75
Los Angeles 60
New York 56
Palermo 55
Medford 54
Des Moines 48
Dallas 46
Hanoi 43
The Dalles 41
Tokyo 41
Lauterbourg 40
Altamura 39
Ho Chi Minh City 39
Princeton 36
Milan 33
Santa Clara 32
Dublin 31
Lawrence 31
Rome 29
Boardman 26
Frankfurt am Main 26
San Diego 24
Buffalo 23
Orem 23
Venice 21
London 17
Hefei 16
Nanjing 16
Brussels 15
São Paulo 15
Brooklyn 14
Chicago 14
Warsaw 14
Amsterdam 13
Chennai 13
Stockholm 13
Phoenix 11
Shanghai 11
Atlanta 10
Biandronno 10
Tashkent 10
Toronto 10
Bremen 9
Changsha 9
Columbus 9
Denver 9
Poplar 9
Falkenstein 8
Guangzhou 8
Montreal 8
Munich 8
Ningbo 8
Jinan 7
Ludwigshafen am Rhein 7
Madrid 7
Mumbai 7
Nanchang 7
Nuremberg 7
San Paolo di Civitate 7
Tianjin 7
Bari 6
Johannesburg 6
Karachi 6
Lappeenranta 6
Lentini 6
Washington 6
Amman 5
Boston 5
Buenos Aires 5
Catania 5
Curitiba 5
Haiphong 5
Jakarta 5
Kumar 5
Mexico City 5
Naaldwijk 5
Redondo Beach 5
Rio de Janeiro 5
Seoul 5
Shenyang 5
Tehran 5
Zhengzhou 5
Asunción 4
Baghdad 4
Totale 4.593
Salva come PNG Salva come JPEG
Nome #
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. 340
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 299
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 275
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity 275
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 269
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. 254
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms 235
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis 222
Immunosenescence and lymphomagenesis 211
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 210
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 209
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study 196
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA. 193
Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients 177
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 174
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors 173
Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer. 170
Cardiovascular risk factor in MPN patients 169
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep 168
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association 167
MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? 161
Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors 161
Age at diagnosis is an important prognostic factor in Philadelphia-negative Myeloproliferative Neoplasms 157
Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature 157
Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review. 147
A case of severe dermatitis in a patient with Polycythemia Vera during cytoreductive therapy 137
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review 135
Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma 135
A Difficult Case of Ventriculitis in a 40-Year-Old Woman with Acute Myeloid Leukemia 133
Bone damage after chemotherapy for lymphoma: a real-world experience 130
PREDICTORS OF RESIDUAL VEIN THROMBOSIS AFTER CANCER-RELATED DEEP VEIN THROMBOSIS OF THE LOWER LIMBS 126
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 122
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 121
Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy 118
High TIM-3 Expression May Contribute to the Functional Impairment of Bone Marrow and Circulating Gamma Delta T Lymphocytes during the Progression of Multiple Myeloma 117
Familial essential thrombocythemia: 6 cases from a mono‐institutional series 116
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different? 114
Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia 114
THE ANTINEOPLASTIC ROLE OF STAT5 INHIBITION IN BCRABL1-POSITIVE CELLS EXPOSED TO PIMOZIDE ALONE AND IN COMBINATION WITH DASATINIB AND PONATINIB 105
Bone damage and health-related quality of life in Hodgkin lymphoma survivors: closing the gaps 102
Nutritional factors and survival in a cohort of patients with myelofibrosis 84
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 83
Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents 76
P-386 A high risk of progression from smoldering to symptomatic multiple myeloma was predicted by bone marrow and circulating gamma delta T cells 66
Totale 7.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 0 0 0 0 0 22 51
2021/2022551 40 60 18 53 13 42 24 31 56 92 48 74
2022/2023755 68 147 23 93 67 125 33 60 106 4 20 9
2023/2024356 15 46 22 78 21 57 31 14 0 10 6 56
2024/2025826 11 41 33 70 53 29 56 87 66 91 130 159
2025/20263.167 245 149 154 283 436 481 467 320 266 252 114 0
Totale 7.303